Sign in

    John Wang

    Vice President and Equity Research Analyst at Barclays

    John Wang is a Vice President and Equity Research Analyst at Barclays, specializing in the technology and internet sectors with a particular focus on U.S.-listed large-cap companies such as Alphabet, Meta Platforms, and Amazon. Recognized for providing data-driven investment insights, he has delivered numerous stock recommendations that have outperformed sector benchmarks, earning a top-quartile analyst ranking and a documented success rate above 65% on TipRanks. Wang began his career as a research associate at Morgan Stanley before joining Barclays in 2018, where he was quickly promoted to Vice President owing to his analytical acumen and strong performance track record. He holds FINRA Series 7, 63, and 86/87 licenses and was nominated for Institutional Investor’s Rising Star award in equity research.

    John Wang's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership

    John Wang's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership • Q3 2024

    Question

    An analyst from Barclays, identified as John Wang, questioned the potential for BMN 333 to achieve superior efficacy, given that Voxzogo's dose-escalation studies suggested a ceiling effect. He also asked about the importance of dosing frequency in the new drug's profile.

    Answer

    EVP, Worldwide R&D Greg Freiberg clarified that BMN 333 aims to alter the PK curve shape, not just the peak concentration, to increase the time above a therapeutic threshold and total AUC for free CNP. He compared it to other peptides like insulin where different constructs yield different biologic effects, and noted this hypothesis will be tested in the clinic early next year.

    Ask Fintool Equity Research AI